aml & mds: mac or ric?
Published 4 years ago • 195 plays • Length 4:39Download video MP4
Download video MP3
Similar videos
-
2:02
oral azacitidine maintenance in aml with mds-related changes: insights from quazar aml-001
-
1:16
ric vs mac in mrd-positive & mrd-negative patients with aml
-
3:02
highlights in aml and mds from eha 2022
-
1:13
cytometry versus morphology in the monitoring of aml
-
2:12
allosct for aml with mds-related features as per the icc and who 2022 classifications
-
1:52
advances in lr-mds and hr-mds in 2023 and beyond
-
1:41
an overview of the mds diagnosis pathway
-
1:57
tolerability and efficacy of magrolimab plus azacitidine in tp53-mutated aml patients
-
2:43
magrolimab azacitidine in tp53-mutant aml
-
9:03
iccs education: minimal/measurable residual disease testing (mrd) by flow cytometry in bll
-
1:04
mp0533, a cd3-engaging darpin, in r/r aml or mds/aml: preliminary results of a phase i/iia trial
-
1:39
how can mrd guide treatment of aml?
-
3:37
the future of aml treatment
-
1:20
prgn-3006 in the treatment of aml and mds
-
1:27
the role of menin inhibitors in the treatment of hr-mds and aml
-
1:35
an overview of the main challenges to prolonging remission in aml
-
1:46
optimizing conditioning regimens in patients with aml undergoing allosct
-
2:45
optimal preparative regimen for aml
-
2:09
advances in the management of fit adults with aml
-
1:05
improving transplantation rates by increasing cr in aml
-
3:37
biomarker analysis of luspatercept versus epoetin alfa in lr-mds in the phase iii commands study